NYSEAMERICAN:BPMXBiopharmx Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Biopharmx Corp Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.82 -0.03 (-1.05 %) (As of 06/5/2020 04:00 PM ET) Add Compare Share Today's Range$2.56Now: $2.82▼$2.9450-Day Range N/A52-Week Range$0.25Now: $2.82▼$1.18Volume1.22 million shsAverage Volume2.15 million shsMarket Capitalization$51.54 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media BioPharmX Corporation, a specialty pharmaceutical company, develops and commercializes novel prescription and over-the-counter (OTC) products that address dermatology and women's health markets. The company offers VI2OLET, an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort, as well as alleviates the symptoms of fibrocystic breast condition (FBC). Its clinical-stage product candidates include BPX01, a topical antibiotic gel that has completed Phase II clinical trials for the treatment of inflammatory lesions of acne; BPX04, a topical antibiotic, which is in pre-Phase II feasibility study for the treatment of inflammatory lesions of rosacea; BPX02, a development stage product candidate for aesthetic dermatology applications; and BPX03, a molecular iodine tablet, which has completed pre-Phase III clinical trial for the treatment of periodic breast pain associated with FBC and cyclic mastalgia. The company serves pharmaceutical companies; physician's practices, including obstetricians and gynecologists, dermatologists, and general practitioners; and retail customers through retail sales channels and/or pharmacy outlets. It has collaboration and license agreement with Iogen LLC to develop molecular iodine formulations; and collaboration and supply agreement with NuTech Medical, Inc. to develop products in the field of dermatology. The company is headquartered in Menlo Park, California.Read More Beat the Market (BTM) Rank™ 3.0 Analyst's Opinion Consensus RatingBiopharmx has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $12.00, Biopharmx has a potential upside of 325.5% from its current price of $2.82.Amount of Analyst CoverageBiopharmx has received no research coverage in the past 90 days. Previous Next 3.1 Community Rank Outperform VotesBiopharmx has received 308 “outperform” votes. (Add your “outperform” vote.)Underperform VotesBiopharmx has received 193 “underperform” votes. (Add your “underperform” vote.)Community SentimentBiopharmx has received 61.48% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Biopharmx and other stocks. Vote “Outperform” if you believe BPMX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BPMX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldBiopharmx does not currently pay a dividend.Dividend GrowthBiopharmx does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Biopharmx insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 3.0Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.22 out of 5 stars Industry, Sector and Symbol Stock Exchange NYSEAMERICAN Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolNYSEAMERICAN:BPMX Previous SymbolNYSE:BPMX CUSIPN/A CIKN/A Webwww.biopharmx.com Phone+1-650-8895020Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees17 Outstanding Shares18,278,000Market Cap$51.54 million Next Earnings Date6/9/2020 (Estimated) OptionableNot Optionable AMEX:BPMX Rates by TradingView Receive BPMX News and Ratings via Email Sign-up to receive the latest news and ratings for BPMX and its competitors with MarketBeat's FREE daily newsletter. Biopharmx (NYSEAMERICAN:BPMX) Frequently Asked Questions Do Wall Street analysts recommend investors buy shares of Biopharmx? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biopharmx in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Biopharmx. When is Biopharmx's next earnings date? Biopharmx is scheduled to release its next quarterly earnings announcement on Tuesday, June 9th 2020. View our earnings forecast for Biopharmx. How were Biopharmx's earnings last quarter? Biopharmx Corp (NYSEAMERICAN:BPMX) released its earnings results on Tuesday, December, 10th. The biotechnology company reported ($1.68) earnings per share for the quarter, topping analysts' consensus estimates of ($2.64) by $0.96. View Biopharmx's earnings history. When did Biopharmx's stock split? How did Biopharmx's stock split work? Biopharmx shares reverse split before market open on Tuesday, May 19th 2020. The 1-12 reverse split was announced on Friday, May 15th 2020. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 18th 2020. An investor that had 100 shares of Biopharmx stock prior to the reverse split would have 8 shares after the split. What price target have analysts set for BPMX? 1 brokers have issued 12 month price targets for Biopharmx's shares. Their forecasts range from $12.00 to $12.00. On average, they anticipate Biopharmx's stock price to reach $12.00 in the next twelve months. This suggests a possible upside of 325.5% from the stock's current price. View analysts' price targets for Biopharmx. Has Biopharmx been receiving favorable news coverage? News headlines about BPMX stock have trended positive on Saturday, InfoTrie reports. The research firm identifies positive and negative press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Biopharmx earned a media sentiment score of 3.0 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the near term. View the latest news aboutBiopharmx. Who are some of Biopharmx's key competitors? Some companies that are related to Biopharmx include Medicenna Therapeutics (MDNA), IMV (IMV), Exicure (XCUR), Emblem (EMC), Pfenex (PFNX), Fennec Pharmaceuticals (FRX), Bioventix (BVXP), Ergomed (ERGO), Exicure (XCUR), Enochian Biosciences (ENOB), Theratechnologies (TH), Rafael (RFL), Pfenex (PFNX), OncoCyte (OCX) and Neuren Pharmaceuticals (NEU). View all competitors. What other stocks do shareholders of Biopharmx own? Based on aggregate information from My MarketBeat watchlists, some companies that other Biopharmx investors own include Sarepta Therapeutics (SRPT), Netlist (NLST), Neovasc (NVCN), Hawkins (HWKN), Novavax (NVAX), CytRx (CYTR), Protalix Biotherapeutics (PLX), Synergy Pharmaceuticals (SGYP), AVEO Pharmaceuticals (AVEO) and Rexahn Pharmaceuticals (REXN). Who are Biopharmx's key executives? Biopharmx's management team includes the following people: Dr. David S. Tierney M.D., Pres, CEO, CFO and Director (Age 55)Dr. Kin Foong Chan, Exec. VP of Research & Technology (Age 45)Dr. José Zayas, Sr. VP of OperationsMs. Joyce Goto, VP, Chief Accounting Officer & Controller (Age 45)Ms. AnnaMarie Daniels, Exec. VP of Clinical & Regulatory Affairs What is Biopharmx's stock symbol? Biopharmx trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "BPMX." How do I buy shares of Biopharmx? Shares of BPMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Biopharmx's stock price today? One share of BPMX stock can currently be purchased for approximately $2.82. How big of a company is Biopharmx? Biopharmx has a market capitalization of $51.54 million. Biopharmx employs 17 workers across the globe. What is Biopharmx's official website? The official website for Biopharmx is www.biopharmx.com. How can I contact Biopharmx? Biopharmx's mailing address is 1505 Adams Dr Ste D, MENLO PARK, CA 94025-1451, United States. The biotechnology company can be reached via phone at +1-650-8895020. This page was last updated on 6/6/2020 by MarketBeat.com Staff
